Cuisinaud G, Legheand J, Llorca G, Belkahia C, Lejeune E, Sassard J
Eur J Clin Pharmacol. 1979 Aug;16(1):59-61. doi: 10.1007/BF00644968.
The pharmacokinetics of fenbufen (3,4-biphenylcarbonyl proprionic acid) a new antiinflammatory agent, and its metabolites, gamma-hydroxy-4-biphenylbutyric acid and 4-biphenylacetic acid have been studied after oral administration to seven patients with rheumatoid arthritis. Fenbufen was administered as a single oral dose of 600 mg in hard gelatine capsules. A specific, sensitive gas chromatographic method was used to measure the concentration of the three compounds. A linear two-compartment open model appeared suitable to describe the course of the plasma level of fenbufen with time. This compound appeared in the blood after a lag time of 0.45 h and the peak plasma concentration of 5.97 micrograms/ml was observed after 1.19 h. The half-life of plasma disappearance was 10.26 h for fenbufen and 10.07 h and at 9.95 for metabolites II and III, respectively.
已对7名类风湿性关节炎患者口服新型抗炎药联苯丁酮酸(3,4 - 联苯羰基丙酸)及其代谢产物γ-羟基-4 - 联苯丁酸和4 - 联苯乙酸后的药代动力学进行了研究。联苯丁酮酸以600毫克的单次口服剂量装入硬明胶胶囊给药。采用一种特异、灵敏的气相色谱法来测定这三种化合物的浓度。线性二室开放模型似乎适合描述联苯丁酮酸血浆水平随时间的变化过程。该化合物在滞后0.45小时后出现在血液中,1.19小时后观察到血浆峰值浓度为5.97微克/毫升。联苯丁酮酸血浆消除半衰期为10.26小时,代谢产物II和III的血浆消除半衰期分别为10.07小时和9.95小时。